1
Richard B Bailey, Dilip K Joshi, Stephen L Michaels, Richard A Wisdom: Production of lactic acid by continuous fermentation using an inexpensive raw material and a simplified method of lactic acid purification. Neurex, Flehr Hohbach Test Albritton & Herbert, September 13, 1988: US04771001 (50 worldwide citation)

The disclosure describes a method for producing lactic acid from carbohydrate-containing media by continuous fermentation utilizing particular methods of media pretreatment, cell-recycle fermentation, fermentation broth acidification, and lactic acid separation.


2
George P Miljanich, Robert S Bitner, Stephen S Bowersox, James A Fox, Karen L Valentino, Donald H Yamashiro: Method of treating ischemia-related neuronal damage. Neurex Corporation, Peter J Dehlinger, September 24, 1991: US05051403 (47 worldwide citation)

A method of reducing neuronal damage related to an ischemic condition in a human patient, such as stroke-induced damage, by administration of a binding/inhibitory omega-conotoxin peptide.


3
George P Miljanich, Robert S Bitner, Stephen S Bowersox, James A Fox, Karen L Valentino, Donald H Yamashiro, Makoto Tsubokawa: Method of reducing neuronal damage using omega conotoxin peptides. Neurex Corporation, Peter J Dehlinger, February 23, 1993: US05189020 (35 worldwide citation)

A partially purified omega conotoxin binding protein is disclosed. The protein, either in partially purified form or in a synaptosomal preparation, is useful in identifying compounds for use in reducing neuronal damage related to an ischemic condition, such as stroke, in a human patient.


4

5
George P Miljanich, Robert S Bitner, Stephen S Bowersox, James A Fox, Karen L Valentino, Donald H Yamashiro, Makoto Tsubokawa: Screening method for neuroprotective compounds. Neurex Corporation, Carol A Stratford, Peter J Dehlinger, November 23, 1993: US05264371 (23 worldwide citation)

A partially purified omega conotoxin binding protein is disclosed. The protein, either in partially purified form or in a synaptosomal preparation, is useful in identifying compounds for use in reducing neuronal damage related to an ischemic condition, such as stroke, in a human patient.


6
George P Miljanich, Robert S Bitner, Stephen S Bowersox, James A Fox, Karen L Valentino, Donald H Yamashiro: Screening method for neuroprotective compounds. Neurex Corporation, Peter J Dehlinger, Carol A Stratford, June 13, 1995: US05424218 (21 worldwide citation)

A partially purified omega conotoxin binding protein is disclosed. The protein, either in partially purified form or in a synaptosomal preparation, is useful in identifying compounds for use in reducing neuronal damage related to an ischemic condition, such as stroke, in a human patient.


7
Gary Arthur Amstutz, Stephen Scott Bowersox, Kishorchandra Gohil, Peter Isadore Adriaenssens, Ramasharma Kristipati: Stable omega conopetide formulations. Neurex Corporation, Peter J Dehlinger, Carol A Stratford, August 18, 1998: US05795864 (19 worldwide citation)

Disclosed are formulations effective to stabilize omega conotoxin peptide preparations at elevated temperatures. Novel omega conopeptides also form part of the invention.


8
Alan Justice, Tejinder Singh, Kishor C Gohil, Karen L Valentino: Method of producing analgesia. Neurex Corporation, Peter J Dehlinger, Carol A Stratford, November 15, 1994: US05364842 (18 worldwide citation)

A method of producing analgesia and enhancing opiate analgesia is disclosed. The method includes administering TVIA (SNX-185) or MVIIA (SNX-111) omega-conopeptide, or derivative thereof which is characterized by its ability to (a) inhibit voltage-gated calcium channels selectively in neuronal tissue ...


9
George P Miljanich, Stephen S Bowersox, James A Fox, Karen L Valentino, Robert S Bitner, Donald H Yamashiro: Delayed treatment method of reducing ischemia-related neuronal damage. Neurex Corporation, Carol A Stratford, Peter J Dehlinger, September 24, 1996: US05559095 (15 worldwide citation)

A method and compositions for reducing neuronal damage related to an ischemic condition in a mammalian subject are described. The method includes administration of a voltage-gated calcium channel-blocking compound to the subject, 4-24 hours after the onset of the ischemic condition. Such a calcium c ...


10